# LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery

> **NCT07168421** · PHASE4 · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 114 (estimated)

## Conditions studied

- Perioperative Myocardial Injury
- Autonomic Dysfunction
- Cardiovascular (CV) Risk
- Major Surgery
- Beta Blocker
- Myocardial Injury After Non-cardiac Surgery

## Interventions

- **DRUG:** Landiolol

## Key facts

- **NCT ID:** NCT07168421
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-24
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-03-01
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168421, "LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07168421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*